Abstract
Activation of the NO-cGMP pathway or adenosine receptors depresses reversibly synaptic transmission in the hippocampus. Here we demonstrate, using the selective A1 receptor antagonist DPCPX, a convergence in the mechanisms of action of the NO donor SNAP, the cGMP phosphodiesterase inhibitor zaprinast and adenosine.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
3',5'-Cyclic-GMP Phosphodiesterases / antagonists & inhibitors
-
Animals
-
Cyclic GMP / physiology*
-
Hippocampus / drug effects
-
Hippocampus / physiology*
-
In Vitro Techniques
-
Neural Pathways / drug effects
-
Neural Pathways / physiology
-
Nitric Oxide / physiology*
-
Penicillamine / analogs & derivatives
-
Penicillamine / pharmacology
-
Purinergic P1 Receptor Antagonists*
-
Purinones / pharmacology
-
Rats
-
S-Nitroso-N-Acetylpenicillamine
-
Signal Transduction / drug effects
-
Signal Transduction / physiology*
-
Synapses / drug effects
-
Synapses / physiology*
-
Synaptic Transmission / drug effects
-
Synaptic Transmission / physiology*
-
Vasodilator Agents / pharmacology
-
Xanthines / pharmacology
Substances
-
Purinergic P1 Receptor Antagonists
-
Purinones
-
Vasodilator Agents
-
Xanthines
-
Nitric Oxide
-
S-Nitroso-N-Acetylpenicillamine
-
1,3-dipropyl-8-cyclopentylxanthine
-
3',5'-Cyclic-GMP Phosphodiesterases
-
Penicillamine
-
zaprinast
-
Cyclic GMP